longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

NOVARTIS AG

NVS

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 20.48, within the reasonable range, cheaper than 30.47% of the time in the past 5 years, and the industry ranks 35/258, the industry Median -1.32.

20.48xP/E
$137.48Stock price
$6.71Earnings per share
20.48xP/E
Stock price$137.48Earnings per share$6.71

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
17.62x
Typical range
9.27x–24.30x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
RHHBYUSRoche
21.93x--$339.04B
RHHVFUSROCHE HOLDINGS AG
23.36x--$361.17B
NVSUSNOVARTIS AG
20.48x2.06%$261.31B
AZNUSAstraZeneca
23.70x--$247.59B
SNYUSSanofi
22.28x20.80%$102.36B
SNYNFUSSanofi
23.12x--$106.25B
CHGCYUSChugai Pharmaceutical
22.41x--$67.49B
MKKGYUSMerck
24.09x--$66.28B
RDYUSDr Reddys Laboratories
27.06x9.81%$9.75B
LGNDUSLigand Pharmac-B
29.24x14.55%$5.77B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.